New QuickMIC® publication in ASM journal
The diagnostics company Gradientech announces a new scientific publication of the QuickMIC® system by Dr. Balmis University General Hospital demonstrating an impressive concordance of 99% between QuickMIC and the reference methods in use.
The study was conducted by Prof. Juan Carlos Rodriguez and colleagues at the Infectious Disease Unit at Dr. Balmis University General Hospital in Alicante, Spain. They evaluated the QuickMIC® system in the rapid diagnosis of the antibiotic susceptibility of Gram-negative bacilli in comparison to the reference methods in use. A total of 816 antibiotic-microorganism combinations were tested, resulting in only eight discrepancies.
According to the authors, “The QuickMIC system excels in rapidly providing susceptibility data for multiple antibiotics against the primary pathogens associated with Gram-negative bacilli bacteraemia. Compared to traditional systems, it demonstrates higher sensitivity and specificity, with a significantly shorter turnaround time and can provide very useful information for the early adjustment of antibiotic treatment.”
“The article emphasises the importance of 2-4 hours test time in combination with the linear MIC values generated by QuickMIC, which enable healthcare providers to make actionable decisions within the same shift. This capability significantly shortens the critical period before implementing corrective treatment, ultimately improving patient outcomes,” says AnnaLotta Schiller, Chief Commercial Officer at Gradientech.
The study is published in Microbiology Spectrum, a peer-reviewed scientific journal published by the American Society for Microbiology (ASM). To access the full article, follow the link below:
https://journals.asm.org/doi/full/10.1128/spectrum.04011-23
The QuickMIC system's ultra-rapid and precise AST results enable sepsis patients to receive specific personalised guidance on the right antibiotic in record time. The modular design offers affordable scaling possibilities, making QuickMIC attractive to both small and large hospital laboratories. QuickMIC and its Gram-negative panel are CE marked and commercially available in Europe but not yet available for sale in the United States.
For further information, please contact:
Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se
AnnaLotta Schiller, PhD, CCO
Tel: +46 733 42 32 93
annalotta.schiller@gradientech.se
About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.
